A Phase 1 interventional study of Alisertib and Itraconazole in Advanced Solid Tumors and Relapsed/Refractory Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 19th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 12 in phase 1, and was the 19th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.
The drug being tested in this study is called alisertib. Alisertib is being tested in adult participants with advanced solid tumors or relapsed refactory lymphoma. The study will look at the effect of the pharmacokinetics (how the drug moves through the body) of alisertib in the presence and absence of itraconazole.
This is an open label study. Participants will receive:
Participation in Part A is approximately 25 days. Part B participation is repeating 21-day cycles. The maximum duration of treatment with alisertib will be 12 months (approximately 16 cycles) unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months.
This multi-center study will take place in the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
Drug: Alisertib · Drug: Itraconazole
Alisertib tablets
Itraconazole oral solution
Also known as: SPORANOX®
Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Number of Participants With Abnormal Laboratory Values Reported as AEs
Standard safety laboratory tests included Chemistry and Hematology. Abnormal laboratory values that led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be a clinically significant change from baseline were reported as AEs.
Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Number of Participants With Clinically Significant Change in Weight Reported as AEs
Change relative to baseline in participant's weight measured throughout study.
Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs
Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).
Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Participants took part in the study at 4 investigative sites in the United States from 22 October 2014 to 21 October 2016. Data cutoff for the primary analysis was 27 March 2015.
| Milestone | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Started | 24 |
| Completed | 19 |
| Not completed | 5 |
| Withdrew: Didn't completed dosing; pk assessment | 5 |
| nmol/L | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A | 1060.3 ± 403.90 | 1002.8 ± 263.81 |
| hr*nmol/L | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A | 15541.6 ± 9119.52 | 20219.5 ± 9930.93 |
| hr*nmol/L | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A | 16804.6 ± 9232.87 | 23488.7 ± 13262.31 |
| L/hr | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A | 4.416 ± 2.4007 | 3.177 ± 1.5765 |
| hr | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A | 2.920 ± 2.3710 | 2.920 ± 2.0244 |
| hr | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A | 22.55 ± 10.316 | 25.37 ± 9.215 |
| nmol/L | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Metabolite 1 (M1) | 409.4 ± 479.92 | 450.0 ± 664.65 |
| Metabolite 2 (M2) | 114.0 ± 52.71 | 103.5 ± 99.28 |
| hr | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Metabolite 1 (M1) | 3.090 (1.00 to 23.10) | 3.800 (1.98 to 10.00) |
| Metabolite 2 (M2) | 9.360 (2.95 to 47.70) | 23.600 (5.73 to 95.30) |
| hr*nmol/L | Alisertib Without Itraconazole | Alisertib With Itraconazole |
|---|---|---|
| Metabolite 1 (M1) | 10550.8 ± 17276.38 | 15776.1 ± 29461.34 |
| Metabolite 2 (M2) | 5880.6 ± 3404.27 | 5081.6 ± 3334.41 |
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| AEs | 24 |
| SAEs | 12 |
Standard safety laboratory tests included Chemistry and Hematology. Abnormal laboratory values that led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be a clinically significant change from baseline were reported as AEs.
| Participants | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Hypokalemia | 3 |
| Elevated blood creatinine | 3 |
| Increased international normalized ratio | 2 |
| Hypercalcemia | 1 |
| Hypomagnesemia | 1 |
| Hypoalbuminemia | 1 |
| Decreased blood potassium | 1 |
| Decreased blood sodium | 1 |
| Elevated blood alkaline phosphatase | 1 |
| Anemia | 5 |
| Neutropenia | 4 |
| Leukopenia | 2 |
| Thrombocytopenia | 2 |
| Decreased lymphocyte count | 2 |
| Decreased white blood cell count | 1 |
| Decreased platelet count | 1 |
Change relative to baseline in participant's weight measured throughout study.
| Participants | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Number of Participants With Clinically Significant Change in Weight Reported as AEs | 2 |
Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).
| Participants | Alisertib Without Itraconazole |
|---|---|
| Pyrexia | 3 |
| Palpitations | 2 |
| Tachycardia | 1 |
Collected over First dose of study drug up to 30 days after the last dose of study drug (up to 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg | 1/24 (4.2%) | 12/24 (50%) | 24/24 (100%) |
| Event | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/24 |
| Abdominal painGastrointestinal disorders | 1/24 |
| ConstipationGastrointestinal disorders | 1/24 |
| Intestinal obstructionGastrointestinal disorders | 1/24 |
| VomitingGastrointestinal disorders | 1/24 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/24 |
| MelaenaGastrointestinal disorders | 1/24 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/24 |
| CellulitisInfections and infestations | 1/24 |
| Herpes zoster disseminatedInfections and infestations | 1/24 |
| Event | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| NauseaGastrointestinal disorders | 11/24 |
| DiarrhoeaGastrointestinal disorders | 10/24 |
| FatigueGeneral disorders | 9/24 |
| VomitingGastrointestinal disorders | 8/24 |
| AlopeciaSkin and subcutaneous tissue disorders | 8/24 |
| StomatitisGastrointestinal disorders | 7/24 |
| HeadacheNervous system disorders | 7/24 |
| ConstipationGastrointestinal disorders | 6/24 |
| Oedema peripheralGeneral disorders | 6/24 |
| Decreased appetiteMetabolism and nutrition disorders | 6/24 |
Safety Population is defined as all participants who received at least 1 dose of any study drug and was used for all safety analyses.
| Age, Continuous(years) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Mean | 61.0 ± 9.52 |
| Sex: Female, Male(Participants) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Female | 13 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 20 |
| Not Reported | 3 |
| Race/Ethnicity, Customized(Participants) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| White | 20 |
| Black or African American | 2 |
| Asian | 1 |
| Other | 1 |
| Region of Enrollment(Participants) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| United States | 24 |
| Height(cm) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Mean | 168.3 ± 8.99 |
| Weight(kg) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Mean | 85.55 ± 25.641 |
| Body Surface Area(m^2) | Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg |
|---|---|
| Mean | 1.983 ± 0.3024 |
Ran from Oct 2014 to primary completion in Mar 2015, 5 months.
Results were first posted in Sep 2019, 4 years 5 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 5 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →